In the BioHarmony Drug Report Database

"Preview" Icon

Daclatasvir

Daklinza (daclatasvir) is a small molecule pharmaceutical. Daclatasvir was first approved as Daklinza on 2015-07-24. It is used to treat chronic hepatitis c and hepatitis c in the USA. Daklinza’s patents are valid until 2031-06-13 (FDA).

 

Trade Name

 

Daklinza
 

Common Name

 

daclatasvir
 

ChEMBL ID

 

CHEMBL2023898
 

Indication

 

chronic hepatitis c, hepatitis c
 

Drug Class

 

Antivirals: NS5A inhibitors

Image (chem structure or protein)

Daclatasvir structure rendering